Studies with clinico-genomics data led to the identification of resistance mechanisms, in particular ESR1 mutations, which are associated with disease progression on aromatase inhibitors (AI) in hormone receptor-positive HER2-negative (HR+/HER2-) breast cancers (BC)15–22. This evidence concerns the gene ESR1 and breast carcinoma.